Beyond its success in migraine and attention deficit hyperactivity disorder, Nu Eyne Co. Ltd. is advancing a portfolio of noninvasive, wearable trigeminal nerve stimulation devices across key three areas of neuromodulation, tissue regeneration and proliferation inhibition.
Guardant Health Inc.agreed to pay more than $900,000 to settle allegations that the company’s human resources office hired a relative and a friend of a physician who persuaded the company to make the hires in a quid pro quo for orders of Guardant’s tests. The U.S. Department of Justice said the penalties could have been much greater but for the company’s cooperation in the investigation, which disclosed that at least one of these hires was not qualified for the position.
University of Regensburg has described water-soluble FLT3 (FLK2/STK1) inhibitors and their prodrugs reported to be useful for the treatment of acute myeloid leukemia (AML).
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
The bromodomain and extraterminal (BET) subfamily contain two similar tandem bromodomains (BD1 and BD2). Selective inhibition of BD2 has been deeply explored; however, the obtention of selective and potent BD1 inhibitors is essential and still lacking.
A researcher at Australia’s Children’s Cancer Institute has been awarded a 3-year US$400,000 grant by the Chadtough Defeat DIPG Foundation to develop and test a new drug candidate for diffuse intrinsic pontine glioma (DIPG).
Previous studies have suggested the importance of cholesterol metabolism in multiple myeloma (MM) cells. Since ferroptosis is closely related to lipid metabolism, researchers from Houston Methodist Research Institute aimed to investigate the crosstalk between metabolic reprogramming and ferroptosis in MM cells.
The industry is looking, with renewed hope, to the “promise” of messenger RNA (mRNA) therapeutics for a wide range of diseases beyond COVID-19, and not only in vaccine form but also for gene and cell therapies.
RSS
